Drug Regulatory Science: Collaborate to improve drug development and evaluation

Peter Mol is professor of drug regulatory science at the University Medical Center Groningen. His research focus is on developing new tools to support regulatory decision-making and the exchange of knowledge between regulatory authorities, health care professionals and lay people. He is currently involved in projects around personalized medicine, new data sources (RWE), patient-centric ways to weigh drug benefit-risk; e.g., using Patient Relevant Outcomes, Quality of Life, and Patient Preference information, and on risk communication; e.g., Direct Healthcare Provider Communication.

He is also a principal assessor at the Dutch Medicines Evaluation Board and a member (vice chair 2016-2022) of EMA’s Scientific Advice Working Party. He has coordinated over 250 scientific advice procedures, providing EMA advice on diabetes, cardiovascular, gynaecological and hematology programs. He is chair of the EMA Cross-Committee Task force on Registries